Get the Stockscreener App
9.36
5.88%
0.52
After Hours:
9.21
-0.15
-1.60%
Monte Rosa Therapeutics Inc stock is traded at $9.36, with a volume of 684.95K.
It is up +5.88% in the last 24 hours and up +83.89% over the past month.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
See More
Previous Close:
$8.84
Open:
$8.85
24h Volume:
684.95K
Relative Volume:
0.35
Market Cap:
$574.45M
Revenue:
-
Net Income/Loss:
$-130.41M
P/E Ratio:
-3.642
EPS:
-2.57
Net Cash Flow:
$-67.76M
1W Performance:
-0.11%
1M Performance:
+83.89%
6M Performance:
+65.66%
1Y Performance:
+161.45%
1-Day Range:
$8.42
$9.37
1-Week Range:
$8.31
$9.68
52-Week Range:
$2.9106
$12.40
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Name
Monte Rosa Therapeutics Inc
Sector
Industry
Phone
617-949-2643
Address
321 HARRISON AVENUE, BOSTON
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-13-22 | Initiated | UBS | Buy |
| Aug-15-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Oct-14-21 | Initiated | SVB Leerink | Mkt Perform |
View All
Monte Rosa Therapeutics Inc Stock (GLUE) Latest News
Wall Street Analysts Believe Monte Rosa Therapeutics (GLUE) Could Rally 67.24%: Here's is How to Trade - MSN
Equities Analysts Issue Forecasts for GLUE FY2024 Earnings - Defense World
Wedbush Research Analysts Lift Earnings Estimates for GLUE - MarketBeat
Monte Rosa Therapeutics price target raised to $20 from $16 at Piper Sandler - Yahoo Finance
Monte Rosa, Novartis Partner To Advance Molecular Glue Degraders - Contract Pharma
Monte Rosa Therapeutics Shares Skyrocket After $2.1 Billion Deal with Novartis - Yahoo Finance
This Biotech Stock Has Doubled Its Value Today—Here's Why - MSN
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - MSN
Monte Rosa Therapeutics stock hits 52-week high at $8.87 By Investing.com - Investing.com Canada
Monte Rosa Therapeutics Soars on Novartis Deal: A Molecular Glue Revolution - BP Journal
Novartis adds another degrader, this time from Monte Rosa - BioCentury
This Biotech Almost Doubled On A Massive Deal With Novartis - Investor's Business Daily
Monte Rosa Therapeutics (NASDAQ:GLUE) Reaches New 52-Week HighTime to Buy? - MarketBeat
Monte Rosa, Novartis have one in VAV1, sign $2.1B pact - BioWorld Online
Boston Biotech Announces Novartis Collaboration - Streetwise Reports
Monte Rosa Therapeutics Target of Unusually High Options Trading (NASDAQ:GLUE) - MarketBeat
Monte Rosa Therapeutics More Than Doubles on Novartis Agreement - MarketWatch
Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis - MSN
Monte Rosa: Novartis Deal Bolsters MGD Platform With Flush Of Cash (NASDAQ:GLUE) - Seeking Alpha
Novartis Signs Global License Agreement with Monte Rosa Therapeutics Worth up to $2.1 Billion to Advance MGD-based Therapeutics - BioPharm International
Monte Rosa Therapeutics, Evoke Pharma, and Autonomix Medical: The Top 3 Stocks Capturing Retail Attention - Barchart
Monte Rosa's stock doubles on multibillion dollar Novartis deal - The Business Journals
Top Gainer Monte Rosa Therapeutics’ Stock Enthralls Retail With Novartis Licensing Deal - Barchart
Monte Rosa Therapeutics stock hits 52-week high at $8.87 - Investing.com India
Monte Rosa scores $2.1B Novartis deal for molecular glue degraders - BioWorld Online
Monte Rosa soars as it inks global license deal with Novartis - The Pharma Letter
Monte Rosa joins with Novartis in ‘molecular glue’ drug deal - BioPharma Dive
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments” - The Globe and Mail
Novartis to pay Monte Rosa $150 million upfront to develop a new class of drugs - Reuters
Why Is Monte Rosa Therapeutics Stock Surging On Monday? - Yahoo Finance
Monte Rosa Therapeutics Shares Soar on Novartis Team-Up - Marketscreener.com
Monte Rosa jumps on $150M license deal with Novartis (NASDAQ:GLUE) - Seeking Alpha
Monte Rosa inks $150 million Novartis deal for MRT-6160 By Investing.com - Investing.com Canada
GLUEMonte Rosa Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Monte Rosa Enters Global License Agreement with Novartis - TipRanks
Monte Rosa inks $150 million Novartis deal for MRT-6160 - Investing.com
Monte Rosa Therapeutics Announces Global License Agreement - GlobeNewswire
Monte Rosa Therapeutics Announces Global License Pact With Novartis To Advance T And B Cell-Modulating Vav1-Directed Molecular Glue Degraders - XM
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders - StockTitan
Monte Rosa reports progress on cancer-targeting molecule By Investing.com - Investing.com Australia
Monte Rosa reports progress on cancer-targeting molecule - Investing.com
Monte Rosa Therapeutics Presents Preclinical Data at the - GlobeNewswire
Objective long/short (GLUE) Report - Stock Traders Daily
Science Spotlight: Better genomic predictors for Black AML patients - BioCentury
Dimensional Fund Advisors LP Has $575,000 Position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Ratio Analysis: Unpacking Monte Rosa Therapeutics Inc (GLUE)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
GLUE’s latest rating updates from top analysts. - Knox Daily
Renaissance Technologies LLC Has $953,000 Stock Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - MarketBeat
American Century Companies Inc. Boosts Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Learn to Evaluate (GLUE) using the Charts - Stock Traders Daily
Versant Venture sells $7.4m in Monte Rosa Therapeutics stock - Investing.com India
Monte Rosa Therapeutics Inc Stock (GLUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):